Genentech Expects To Miss Enbrel Manufacturing Deadlines; Amgen Will Not Reimburse Equipment
This article was originally published in The Pink Sheet Daily
Executive Summary
A Genentech SEC filing notes that milestones such as FDA approval of the manufacturing process would not be met in the agreed upon timeline.
You may also be interested in...
Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected
Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.
Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected
Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.
Amgen Expects Enbrel Prefilled Syringes To "Blunt" Humira Competition
The company will launch the new delivery device by the end of November, one month ahead of schedule. Enbrel's growth has been driven by performance in psoriasis, where the product holds the vast majority of market share among biologics.